Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-019 (padnarsertib) in advanced solid tumors or Non-Hodgkin's Lymphoma
NCT04281420Phase 1Terminated
- Sponsor
- Antengene
- Start
- Apr 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of padnarsertib in solid tumor and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Antengene. Primary endpoints: Maximum Tolerated Dose at 18 months, Dose-Limiting Toxicity at 18 months and 1 more. Started Apr 2020; status: terminated.
02
Drugs
padnarsertib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04281420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281420.